SIGA Technologies, Inc. to be Added to the Russell 3000(r) and Russell Global(r)...

SIGA Technologies, Inc. to be Added to the Russell 3000(r) and Russell Global(r)
Indices

NEW YORK, June 26, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc.
(Nasdaq:SIGA), a company specializing in the development of pharmaceutical
agents to fight biowarfare pathogens, announced today that it will be added to
the Russell 3000(r) and the Russell Global(r) Indices, following Russell
Investment Group's annual reconstitution of its family of indices on June 26,
2009, after the U.S. markets close. The Russell 3000 Index measures the
performance of the largest 3000 U.S. companies representing approximately 98% of
the investable U.S. equity market and serves as the U.S. component to the
Russell Global Index.

"SIGA's inclusion in the Russell 3000 is another validation of the Company's
development over this past year. We have worked hard to bring the Company to
where it is today and we believe this milestone reflects our commitment to
growing SIGA and adding value to our shareholders," said Dr. Eric Rose, SIGA's
Chairman and CEO. "Becoming a member of the Russell 3000 will increase the
visibility of our stock and generate greater awareness of our business within
the investment community."

Membership in the Russell 3000 means SIGA is automatically included in the
small-cap Russell 2000 Index as well as the appropriate growth and value style
indexes. Russell provides its equity index family to investment managers and
institutional investors for index funds and as benchmarks for both passive and
active investment strategies. According to Russell, $4 trillion in assets
currently are benchmarked to its indices. Total returns data for the Russell
Indexes are available at http://www.russell.com/Indexes/performance/default.asp.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated
computational modeling in the design and development of novel products for the
prevention and treatment of serious infectious diseases, with an emphasis on
products for biological warfare defense. SIGA believes that it is a leader in
the development of pharmaceutical agents to fight potential bio-warfare
pathogens. SIGA has antiviral programs targeting smallpox and other Category A
pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito,
Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses
(Ebola and Marburg). For more information about SIGA, please visit SIGA's web
site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements

This press release contains or implies certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including statements regarding the efficacy of potential products, the
timelines for bringing such products to market and the continued development and
possible eventual approval of such products. Forward-looking statements are
based on management's estimates, assumptions and projections, and are subject to
uncertainties, many of which are beyond SIGA's control. Actual results may
differ materially from those anticipated in any forward-looking statement.
Factors that may cause such differences include the risks that (i) potential
products that appear promising to SIGA or its collaborators cannot be shown to
be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) SIGA
or its collaborators will not obtain appropriate or necessary governmental
approvals to market these or other potential products, (iii) SIGA may not be
able to obtain anticipated funding for its development projects or other needed
funding, (iv) SIGA may not be able to secure funding from anticipated government
contracts and grants, (v) SIGA may not be able to secure or enforce sufficient
legal rights in its products, including sufficient patent protection for its
products, (vi) regulatory approval for SIGA's products may require further or
additional testing that will delay or prevent approval, (vii) the Biomedical
Advanced Research & Development Authority may not complete the procurement set
forth in its solicitation for the acquisition of a smallpox antiviral for the
strategic national stockpile, or may complete it on different terms; (viii)
SIGA's proposed drug candidate for responding to any governmental solicitation
for purchase may not meet the requirements of the solicitation; (ix) the
volatile and competitive nature of the biotechnology industry may hamper SIGA's
efforts, (x) changes in domestic and foreign economic and market conditions may
adversely affect SIGA's ability to advance its research or its products, and
(xi) changing federal, state and foreign regulation on SIGA's businesses may
adversely affect SIGA's ability to advance its research or its products. More
detailed information about SIGA and risk factors that may affect the realization
of forward-looking statements, including the forward-looking statements in this
press release, is set forth in SIGA's filings with the Securities and Exchange
Commission, including SIGA's Annual Report on Form 10-K for the fiscal year
ended December 31, 2008, and in other documents that SIGA has filed with the
Commission. SIGA urges investors and security holders to read those documents
free of charge at the Commission's Web site at http://www.sec.gov. Interested
parties may also obtain those documents free of charge from SIGA.
Forward-looking statements speak only as to the date they are made, and, except
for any obligation under the U.S. federal securities laws, SIGA undertakes no
obligation to publicly update any forward-looking statement as a result of new
information, future events or otherwise.

-0-
CONTACT: KCSA Strategic Communications
Todd Fromer
212-896-1215
Tfromer@kcsa.com
Marybeth Csaby
212-896-1236
mcsaby@kcsa.com